J&J

Showing 15 posts of 219 posts found.

jj

J&J’s Baby powder tested in India and Bangladesh

December 21, 2018
Medical Communications Bangladesh, Cancer, India, J&J, JJ, asbestos

Bangladeshi authorities will collect and test samples of Johnson & Johnson’s baby powders for traces of cancer causing asbestos, after …

jj_sign_on_wall

Indian authorities seize J&J Baby Powder in response to Reuters report

December 19, 2018
Research and Development Cancer, India, J&J, JJ, asbestos, baby powder, regulation

Indian authorities have seized samples of Johnson & Johnson’s Baby Powder from a factory in Baddi in Northern India, after …

johnson_and_johnson_jj

J&J announces $5bn share repurchase

December 18, 2018
Manufacturing and Production J&J, JJ, Shares, asbestos, baby powder, reuters, scandal

New Jersey-based pharma firm Johnson & Johnson plans to buy back $5 billion in shares after news agency Reuters released …

J&J shares plummet after asbestos cover up allegations emerge

December 17, 2018
Sales and Marketing J&J, JJ, Johnson & Johnson, asbestos, reuters

Shares in American healthcare firm Johnson & Johnson plummeted on Friday after news agency Reuters reported that the New Jersey-based …

gsk_china_2_2_0_1

GSK retain top spot on access to medicines list

November 22, 2018
Business Services, Research and Development GSK, J&J, JJ, R&D, Sanofi, access, low and middle income countries, researh

The majority (63%) of research and development projects are being conducted by just five companies; GSK, Johnson & Johnson, Sanofi, …

janssen_latest_logo_on_sign_closer

J&J buy global rights to Yuhan’s lazertinib in deal worth $1.2bn

November 6, 2018
Manufacturing and Production J&J, JJ, NSCLC, Yuhan, deal, lazertinib, south korea

Johnson & Johnson’s Janssen Biotech unit has bought the rights to Yuhan’s third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib in a deal …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

November 2, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, GSK, ITH Pharma, J&J, JJ, NICE, Sanofi, Trump, top 10

Deals dominated the headlines this week as both Sanofi and AstraZeneca made billion dollar agreements. Meanwhile, the FDA gave magic …

J&J’s Invokana becomes first FDA-approved oral diabetes drug to reduce cardiovascular event risk

October 31, 2018
Research and Development, Sales and Marketing FDA, J&J, JJ, invokana, pharma

The FDA has given the go-ahead for Johnson & Johnson’s drug Invokana (canagliflozin) for use in the risk reduction of …

US court overturns J&J’s Zytiga patent in combination with prednisone

October 29, 2018
Sales and Marketing J&J, JJ, Johnson and Johnson, Zytiga, court, generic, prednisone

A court in New Jersey has invalidated Johnson & Johnson’s patent on the prostate cancer drug Zytiga when used in …

top_10_image

Top Ten most popular articles on Pharmafile.com this week!

October 26, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, GSK, HDA, J&J, JJ, brexit, clinical trials, pharmafile, resutls, stockpiling, top 10

Winter is coming! And with it an assortment of promising and not so promising results from big pharma. While J&J …

J&J announce promising Phase 1/2a results for HIV vaccine

October 23, 2018
Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases

The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …

GSK named third best UK workplace

October 22, 2018
Sales and Marketing AbbVie, Amgen, BMS, Eli Lilly, GSK, J&J, JJ, work

British multinational GlaxoSmithKline has been rated as the third best company to work for in the UK, according to jobs …

jj_sign_on_wall

J&J pledges to end global TB pandemic

September 25, 2018
Manufacturing and Production J&J, JJ, Johnson and Johnson, TB, access, tuberculosis

Johnson and Johnson have announced that they are launching a 10-year initiative aimed at helping to end tuberculosis, the world’s …

janssen_latest_logo_on_sign

Europe approves Janssen’s Darzalex in frontline multiple myeloma

September 4, 2018
Manufacturing and Production, Research and Development, Sales and Marketing EU, Europe, J&J, JJ, Janssen, darzalex, multiple myeloma, pharma

Janssen has revealed that its CD38-targeting biologic drug Darzalex (daratumumab) has received approval from the European Commission, authorising its use …

Latest content